SGLT-2 inhibitors as cardioprotective agents in COVID-19

Gupta, Kashish; Kunal, Shekhar

doi:10.1016/j.hrtlng.2020.09.002

Cited by 10 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may have a putative role in COVID-19 patients with myocarditis and adverse cardiac remodeling. SGLT2i also downregulates the expression of inflammatory genes and reduces oxidative stress, leading to cardiorenal dysfunction's amelioration (83).…”

Section: Sglt2-inhibitorsmentioning

confidence: 99%

Type 2 Diabetes Mellitus and COVID-19: A Narrative Review

Corrao

Pinelli²,

Vacca³

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

The pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has involved more than one hundred million individuals, including more than two million deaths. Diabetes represents one of the most prevalent chronic conditions worldwide and significantly increases the risk of hospitalization and death in COVID-19 patients. In this review, we discuss the prevalence, the pathophysiological mechanisms, and the outcomes of COVID-19 infection in people with diabetes. We propose a rationale for using drugs prescribed in patients with diabetes and some pragmatic clinical recommendations to deal with COVID-19 in this kind of patient.

show abstract

Section: Sglt2-inhibitorsmentioning

confidence: 99%

Type 2 Diabetes Mellitus and COVID-19: A Narrative Review

Corrao

Pinelli²,

Vacca³

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Previous studies have demonstrated that SGLT2is can prevent or suppress the inflammatory processes during different pathophysiologic conditions such as DM, irritable bowel syndrome, renal disorders, atherosclerosis and neurodegenerative complications 59–62 . Furthermore, more recent evidence suggests that SGLT2is may improve COVID‐19 dependent inflammation, 25 and it has been suggested that these anti‐inflammatory benefits of SGLT2is have potential therapeutic utility against COVID‐19 25,63 . This has led to the initiation of a multinational clinical trial (DARE‐19; http://clinicaltrials.gov: NCT04350593) that is testing dapagliflozin ‐a SGLT2i‐ in COVID‐19 disease patients with respiratory complications.…”

Section: Anti‐inflammatory Effects Of Sglt2iand Covid‐19mentioning

confidence: 99%

Anti‐inflammatory effects of sodium‐glucose cotransporter‐2 inhibitors in COVID‐19

et al. 2023

View full text Add to dashboard Cite

The ongoing pandemic of COVID-19 is intrinsically a systemic inflammatory disorder; hence, those patients suffering an underlying chronic inflammatory disease such as diabetes mellitus are at high risk of severe complications. Preventing or suppressing the inflammatory responses are of importance in diabetic patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are a newly introduced anti-diabetic drugs that have hypoglycemic effects through the urinary excretion of glucose. They also have an anti-inflammatory potential in diabetes patients, in addition to improving glycemic control, and while there is no direct data available in diabetic patients with COVID-19 disease, there is evidence that suggests that SGLT2i can reduce systemic inflammation and diminish the cytokine storm effect via several cellular mechanisms. In the current review, our aim was to classify and describe the molecular and cellular pathways by which SGLT2i have anti-inflammatory effects in diabetic patients with COVID-19 disease.

show abstract

“…These drugs, also called gliflozins, are a new class of anti-diabetic drugs, which inhibit sodium-glucose cotransporter 2 (SGLT2) facilitative co-transporter of glucose, which is found in proximal convoluted tubule (PCT) of nephrons; this transporter promotes the urinary excretion of glucose, which in turn suppresses elevated plasma glucose levels in T2DM patients (81)(82)(83). The fall in glucose levels ushers an improvement in glycemic indices (84)(85)(86).…”

Section: Mechanism Of Actionmentioning

confidence: 99%

Impact of Antidiabetic Drugs on Risk and Outcome of Covid-19 Infection: A Review

Zainal¹,

Merkhan²

2022

MMSL

View full text Add to dashboard Cite

Based on many reports, an unmistakable link probably exists between diabetes mellitus and COVID-19. A major predisposing factor determining severity and mortality of COVID-19 is diabetes mellitus, diabetic patients were shown to be at higher risk for developing severe COVID-19 disease than non-diabetics; many recent studies reported a striking prevalence of DM in those diagnosed with COVID-19. Accordingly, antidiabetic drugs can possibly impact the clinical course and / or the outcome of this infection, either by alleviating diabetes-associated symptoms, minimizing its complications, or by mitigating or aggravating COVID-19 disease by effects independent from their direct antidiabetic effects. Several antidiabetic drug classes were shown to have varying effects, like blocking viral entry to cells, as well as having immunomodulatory, anti-inflammatory, antifibrotic, or cardioprotective effects; such effects could prove beneficial for COVID-19 patients. On the other hand, some antidiabetic agents may have adverse effects that aggravate patients' condition like hypoglycemia, fluid retention, increased weight or lactic acidosis, which require special consideration in patient management. Some of the drugs were found in observational studies to either reduce mortality from COVID-19 or pose no harm, but more solid evidence from clinical trials is still lacking.

show abstract

SGLT-2 inhibitors as cardioprotective agents in COVID-19

Cited by 10 publications

References 12 publications

Type 2 Diabetes Mellitus and COVID-19: A Narrative Review

Type 2 Diabetes Mellitus and COVID-19: A Narrative Review

Anti‐inflammatory effects of sodium‐glucose cotransporter‐2 inhibitors in COVID‐19

Impact of Antidiabetic Drugs on Risk and Outcome of Covid-19 Infection: A Review

Contact Info

Product

Resources

About